What is Rhodiola rosea?
Rhodiola rosea is a hardy perennial herb native to the Arctic and mountainous regions of Europe and Asia. It has been used in traditional medicine in Russia, Scandinavia, and China for centuries as an adaptogen — a compound claimed to increase non-specific resistance to stress. The root extract is standardised to two primary bioactive families: rosavins (unique to R. rosea) and salidroside (also found in other plants). Quality products specify both. [1]
The standardisation threshold widely used in clinical research is ≥3% rosavins and ≥1% salidroside. Products not meeting this specification — or specifying only salidroside without rosavins — are not equivalent to what was studied in the RCTs. Indian market products frequently lack the extract specification on the label. [2]
Standardisation is everything
Rhodiola products vary from truly standardised extracts (≥3% rosavins, ≥1% salidroside) to crude root powder with no active fraction guarantee. The RCT evidence is on standardised extracts only. A product saying 'rhodiola rosea 500mg' without naming the extract ratio could contain virtually no active compounds. This is the dominant quality failure mode in the India market.
How Rhodiola works
The proposed mechanisms are multiple and not fully characterised. Salidroside inhibits monoamine oxidase (MAO) — the enzyme that degrades serotonin, dopamine, and noradrenaline — which may explain mood and fatigue effects. Rosavins are proposed to activate adenylyl cyclase and cAMP pathways in muscle tissue. Both compound families exhibit anti-oxidant and anti-inflammatory properties in preclinical models. The HPA-axis modulating effect (reducing cortisol release) has been observed in some human trials but is less consistent than in ashwagandha. [3]
Clinical evidence
| Study | Design | n | Key finding | Grade |
|---|---|---|---|---|
| Shevtsov et al. (2003) — Fatigue, single dose doi:10.1055/s-2003-39807 | RCT, crossover | n=161 | Single 370 mg rhodiola extract (SHR-5) significantly reduced mental fatigue on Anti-Fatigue Index (AFI) vs. placebo in night-shift physicians. Acute effect within 2 hours; most cited rhodiola RCT for anti-fatigue. | B |
| Olsson et al. (2009) — Stress & fatigue doi:10.1080/13651500802642838 | RCT, 4 weeks | n=60 | WS® 1375 extract (200 mg BID) significantly reduced burnout scores, fatigue, and improved attention/speed-of-cognitive-function vs. placebo in stress-fatigued individuals. | B |
| Hung et al. (2011) — Meta-analysis doi:10.1016/j.phymed.2010.08.014 | Systematic review, 11 RCTs | n=— | Rhodiola showed consistent benefit for physical performance, mental fatigue, and depression across multiple RCTs, with a favourable safety profile. Effect sizes generally modest. | B |
| Mao et al. (2015) — Depression doi:10.1080/13651501.2015.1016082 | RCT, 12 weeks | n=57 | Rhodiola (SHR-5, 340–680 mg/day) vs. sertraline vs. placebo: rhodiola had fewer side effects and similar (non-statistically significant) improvement in depression scores to sertraline, though both outperformed placebo modestly. | C |
Dosage & protocol
Evidence-based dosing
200–400 mg/day of a standardised extract (≥3% rosavins, ≥1% salidroside), taken in the morning or early afternoon. For acute anti-fatigue effect: single doses of 300–600 mg used in some RCTs. Most chronic-use studies use 8–12 week protocols. Avoid evening dosing — mildly stimulating effect may disrupt sleep for sensitive individuals. Cycle periodically (8 weeks on, 2 weeks off) as a precaution, though tolerance data is limited.
India-specific context
Not native to India — mostly imported extract, quality uneven
Rhodiola rosea is not native to India and all available extract is imported (primarily from Russia, China, and Scandinavia). Quality control for imported botanicals in India is inconsistent — the extract standardisation on the label is rarely independently verified. The Indian rhodiola market has high consumer interest but limited verified product supply. Himalaya does not offer rhodiola. Most available products are from smaller Indian supplement brands or international brands available via Amazon.in.
Third-party lab test data
Indian brand comparison
| Brand | Extract spec | ₹/300mg dose | Standardisation verified | Our take |
|---|---|---|---|---|
| Nutrabay Rhodiola Rosea | ≥3% rosavins, ≥1% salidroside | ₹28 | COA on request | Most transparently specified Indian option. Acceptable if COA confirms standardisation. |
| WOW Life Science Rhodiola | Not specified on label | ₹22 | No | No standardisation stated. Skip. |
| NOW Foods Rhodiola (imported) | ≥3% rosavins | ₹38 | Yes (NSF certified) | Best quality globally. Import pricing makes it expensive; authentic on Amazon.in with caution. |
| Generic 'rhodiola 500mg' capsules | Not standardised | ₹12–18 | No | Avoid. No active fraction guarantee. Evidence does not apply. |
Scoring rubric — full breakdown
1. Evidence quality
Moderate RCT base with consistent directional findings for mental fatigue and stress resilience. However, most trials are small (n=30–161), with short follow-up, and using proprietary extracts (SHR-5, WS®1375) not available as standalone India products. The Cochrane-level review has not been done. Effect sizes are modest. Evidence is encouraging but not at the strength of creatine, caffeine, or vitamin D.
2. Dosage confidence
200–400 mg/day of standardised extract is the consensus range from clinical trials. Dose-response relationship not well-characterised above 600 mg. The acute anti-fatigue use (single doses) is distinct from chronic adaptogen use — dosing protocol depends on which outcome you are targeting. Good enough to be actionable.
3. India market fit
High demand but supply-side quality problem: rhodiola is not native to India, most products are imported without independent verification, and standardisation claims are rarely backed by COA. The extract required (SHR-5 or equivalent) is not commonly manufactured in India. Consumer has to work harder here to find a verified product vs. ashwagandha.
4. Safety profile
Good safety profile across all clinical trials — no serious adverse events reported. Minor stimulating effect in some users (insomnia, agitation at high doses). Mild GI discomfort in small minority. Theoretical interaction with monoamine drugs (due to MAO inhibition) warrants caution for those on antidepressants. Not well-studied in pregnancy.
5. Label accuracy (tested)
The worst-performing category on this rubric — 40% of consumer products failed to contain the stated rosavin/salidroside levels in the limited testing available. Many products sell crude powder with no extract standardisation. This is the primary reason Rhodiola scores lower overall than its evidence would otherwise merit. Only buy brands that publish COA with HPLC-verified rosavin and salidroside content.
References
- 1Panossian A, Wikman G. Effects of adaptogens on the central nervous system and the molecular mechanisms associated with their stress-protective activity. Pharmaceuticals. 2010. doi:10.3390/ph3010188
- 2Ishaque S, et al. Rhodiola rosea for physical and mental fatigue: a systematic review. BMC Complement Altern Med. 2012. doi:10.1186/1472-6882-12-70
- 3Darbinyan V, et al. Clinical trial of Rhodiola rosea L. extract SHR-5 in the treatment of mild to moderate depression. Nord J Psychiatry. 2007. doi:10.1080/08039480701643290
- 4Shevtsov VA, et al. A randomized trial of two different doses of a SHR-5 Rhodiola rosea extract versus placebo and control of capacity for mental work. Phytomedicine. 2003. doi:10.1078/094471103321659780
Disclosures: Naked Compound participates in Amazon.in affiliate programme. Some links earn a small commission. Full policy: conflicts-policy.html